Decreased cardiac lipoprotein lipase activity in rats treated chronically with adriamycin.
Rats treated chronically with the anticancer agent adriamycin (1.5 mg/kg/week X 14 weeks) exhibited cardiac and renal lesions typical of anthracycline toxicity, and had serum hyperlipidemia characterized by 4 to 10 fold elevations in all lipoprotein classes. Heparin-releasable lipoprotein lipase activity measured in perfused heart preparations was decreased 69% in adriamycin-treated rats compared to saline-treated controls. Residual (non-heparin-releasable) activity was not significantly different after adriamycin treatment. The decrease in functional cardiac lipoprotein lipase may account, at least in part, for the serum hyperlipidemia observed in adriamycin-treated rats, and might play a role in the development of heart muscle disease.
D000818:Animals; D002784:Cholesterol / Q000097:blood; D004317:Doxorubicin / Q000494:pharmacology*; D004587:Electrophoresis, Agar Gel; D006321:Heart / Q000187:drug effects; D006493:Heparin / Q000494:pharmacology; D007668:Kidney / Q000187:drug effects; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D009206:Myocardium / Q000201:enzymology*; D009929:Organ Size / Q000187:drug effects; D051381:Rats; D011916:Rats, Inbred F344; D014280:Triglycerides / Q000097:blood
D008074:Lipoproteins; D014280:Triglycerides; D004317:Doxorubicin; D006493:Heparin; D002784:Cholesterol; D008071:Lipoprotein Lipase